Thymidylate synthase inhibitors for non-small cell lung cancer
作者： Elena Galvani , Godefridus J Peters , Elisa Giovannetti
DOI: 10.1517/13543784.2011.617742
关键词:
摘要: Introduction: The folate-dependent enzyme thymidylate synthase (TS) plays a pivotal role in DNA replication/repair and cancer cell proliferation, represents valid target for the treatment of several tumor types, including NSCLC. NSCLC is leading cause cancer-related mortality, TS inhibitors have gone into preclinical clinical testing, with pemetrexed emerging its approval widespread use as first-/second-line maintenance therapy this disease. Areas covered: This review summarizes therapeutic options NSCLC, well background rationale targeting TS. authors also recent pharmacogenetic studies data from trials evaluating novel inhibitors, hoping that reader will gain comprehensive overview field inhibition, specifically relating to drugs used or being developed lung patients. Expert opinion: validated However, benefits conventional chemotherapy hav...
narcis.nl参考文章(108)
Tamila Kindwall-Keller, Gregory A. Otterson, Donn Young, Anterpreet Neki, Tamara Criswell, Gerard Nuovo, Richie Soong, Robert Diasio, Miguel A. Villalona-Calero, Phase II Evaluation of Docetaxel-Modulated Capecitabine in Previously Treated Patients with Non–Small Cell Lung Cancer Clinical Cancer Research. ,vol. 11, pp. 1870- 1876 ,(2005) , 10.1158/1078-0432.CCR-04-1727
I. David Goldman, Marie Hanscom, Shubing Zhang, Rongbao Zhao, Shrikanta Chattopadhyay, Loss of Reduced Folate Carrier Function and Folate Depletion Result in Enhanced Pemetrexed Inhibition of Purine Synthesis Clinical Cancer Research. ,vol. 11, pp. 1294- 1301 ,(2005)
Nicholas J. Vogelzang, James J. Rusthoven, James Symanowski, Claude Denham, E. Kaukel, Pierre Ruffie, Ulrich Gatzemeier, Michael Boyer, Salih Emri, Christian Manegold, Clet Niyikiza, Paolo Paoletti, Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma Journal of Clinical Oncology. ,vol. 21, pp. 2636- 2644 ,(2003) , 10.1200/JCO.2003.11.136
Martin Reck, Tony Mok, Jürgen Wolf, David Heigener, Yi-long Wu, Reviewing the safety of erlotinib in non-small cell lung cancer. Expert Opinion on Drug Safety. ,vol. 10, pp. 147- 157 ,(2011) , 10.1517/14740338.2011.540799
J DeGregori, T Kowalik, J R Nevins, Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes. Molecular and Cellular Biology. ,vol. 15, pp. 4215- 4224 ,(1995) , 10.1128/MCB.15.8.4215
Takafumi Okabe, Isamu Okamoto, Sayaka Tsukioka, Junji Uchida, Tsutomu Iwasa, Takeshi Yoshida, Erina Hatashita, Yuki Yamada, Taroh Satoh, Kenji Tamura, Masahiro Fukuoka, Kazuhiko Nakagawa, Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase. Molecular Cancer Therapeutics. ,vol. 7, pp. 599- 606 ,(2008) , 10.1158/1535-7163.MCT-07-0567
Norman L Lehman, Future potential of thymidylate synthase inhibitors in cancer therapy. Expert Opinion on Investigational Drugs. ,vol. 11, pp. 1775- 1787 ,(2002) , 10.1517/13543784.11.12.1775
Bjørn H. Grønberg, Roy M. Bremnes, Øystein Fløtten, Tore Amundsen, Paal Fr. Brunsvig, Harald H. Hjelde, Stein Kaasa, Christian von Plessen, Frøydis Stornes, Terje Tollåli, Finn Wammer, Ulf Aasebø, Stein Sundstrøm, Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed Plus Carboplatin Compared With Gemcitabine Plus Carboplatin As First-Line Chemotherapy in Advanced Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 27, pp. 3217- 3224 ,(2009) , 10.1200/JCO.2008.20.9114
Ken Takezawa, Isamu Okamoto, Junko Tanizaki, Kiyoko Kuwata, Haruka Yamaguchi, Masahiro Fukuoka, Kazuto Nishio, Kazuhiko Nakagawa, Enhanced Anticancer Effect of the Combination of BIBW2992 and Thymidylate Synthase-Targeted Agents in Non-Small Cell Lung Cancer with the T790M Mutation of Epidermal Growth Factor Receptor Molecular Cancer Therapeutics. ,vol. 9, pp. 1647- 1656 ,(2010) , 10.1158/1535-7163.MCT-09-1009
J. Galivan, G. Pizzorno, M. A. Bunni, D. G. Priest, A. R. Cashmore, B. A. Moroson, O. Russello, J. R. Mayer, G. P. Beardsley, Multifactorial Resistance to 5,10-Dideazatetrahydrofolic Acid in Cell Lines Derived from Human Lymphoblastic Leukemia CCRF-CEM Cancer Research. ,vol. 55, pp. 566- 573 ,(1995)